MTA1 overexpression induces cisplatin resistance innasopharyngeal carcinoma by promoting cancer stem cells properties

Molecules and Cells

Volumn 37, Issue 9, 2014, Pages 699-704

  Feng, Xiaohua ^b   Zhang, Qianbing ^c   Xia, Songxin ^d   Xia, Bing ^f   Zhang, Yue ^c,f   Deng, Xubin ^c   Su, Wenmei ^e   Huang, Jianqing ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINE   (China)

^e GUANGDONG MEDICAL UNIVERSITY   (China)

^f No 458 Hospital of Chinese People's Liberation Army   (China)

Author keywords

Cancer stem cell; Cisplatin resistance; MTA1; Nasopharyngeal carcinoma

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CISPLATIN; METASTASIS ASSOCIATED GENE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TUMOR PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE; MTA1 PROTEIN, HUMAN; REPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL LINE; CANCER INHIBITION; CANCER RESISTANCE; CANCER STEM CELL; CONTROLLED STUDY; DRUG SENSITIVITY; ECTOPIC EXPRESSION; ENZYME INHIBITION; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; ONCOGENE; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE SILENCING; GENETICS; HUMAN; METABOLISM; NASOPHARYNGEAL NEOPLASMS; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HISTONE DEACETYLASES; HUMANS; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; NEOPLASTIC STEM CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; REPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84914140403     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.14348/molcells.2014.0029     Document Type: Article

References (24)

1. Barr, M.P., Gray, S.G., Hoffmann, A.C., Hilger, R.A., Thomale, J., O’Flaherty, J.D., Fennell, D.A., Richard, D., O’Leary, J.J., and O’Byrne, K.J. (2013). Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One 8, e54193.
2. Bui-Nguyen, T.M., Pakala, S.B., Sirigiri, R.D., Xia, W., Hung, M.C., Sarin, S.K., Kumar, V., Slagle, B.L., and Kumar, R. (2010). NFkappaB signaling mediates the induction of MTA1 by hepatitis B virus transactivator protein HBx. Oncogene 29, 1179-1189.
3. Donnenberg, V.S., and Donnenberg, A.D. (2005). Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J.Clin.Pharmacol. 45, 872-877.
4. Godwin, P., Baird, A.M., Heavey, S., Barr, M.P., O’Byrne, K.J., and Gately, K. (2013). Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Front.Oncol. 3, 120.
5. Kumar, R., Wang, R.A., and Bagheri-Yarmand, R. (2003). Emerging roles of MTA family members in human cancers. Semi.Oncol. 30, 30-37.
6. Kumar, R., Balasenthil, S., Pakala, S.B., Rayala, S.K., Sahin, A.A., and Ohshiro, K. (2010). Metastasis-associated protein 1 short form stimulates Wnt1 pathway in mammary epithelial and cancer cells. Cancer Res. 70, 6598-6608.
7. Li, D.Q., Pakala, S.B., Nair, S.S., Eswaran, J., and Kumar, R. (2012a). Metastasis-associated protein 1/nucleosome remodeling and histone deacetylase complex in cancer. Cancer Res. 72, 387-394.
8. Li, Y., Huang, W., Huang, S., Du, J., and Huang, C. (2012b). Screening of anti-cancer agent using zebrafish: comparison with the MTT assay. Biochem.Biophys.Res.Commun. 422, 85-90.
9. Liu, A.Y., Cai, Y., Mao, Y., Lin, Y., Zheng, H., Wu, T., Huang, Y., Fang, X., Lin, S., Feng, Q., et al. (2014). Twist2 promotes self-renewal of liver cancer stem-like cells by regulating CD24. Carcinogenesis 35, 537-545.
10. Ma, B.B., Lui, V.W., Hui, E.P., Lau, C.P., Ho, K., Ng, M.H., Cheng, S.H., Tsao, S.W., and Chan, A.T. (2010). The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. Invest. New Drugs 28, 413-420.
11. Ma, L., Zhang, G., Miao, X.B., Deng, X.B., Wu, Y., Liu, Y., Jin, Z.R., Li, X.Q., Liu, Q.Z., Sun, D.X., et al. (2013). Cancer stem-like cell properties are regulated by EGFR/AKT/beta-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma. FEBS J. 280, 2027-2041.
12. Morais, C., Gobe, G., Johnson, D.W., and Healy, H. (2010). Inhibition of nuclear factor kappa B transcription activity drives a synergistic effect of pyrrolidine dithiocarbamate and cisplatin for treatment of renal cell carcinoma. Apoptosis 15, 412-425.
13. Nagaraj, S.R., Shilpa, P., Rachaiah, K., and Salimath, B.P. (2013). Crosstalk between VEGF and MTA1 signaling pathways contrib-ute to aggressiveness of breast carcinoma. Mol. Carcinog. [Epub ahead of print].
14. Reddy, S.D., Pakala, S.B., Molli, P.R., Sahni, N., Karanam, N.K., Mudvari, P., and Kumar, R. (2012). Metastasis-associated protein 1/histone deacetylase 4-nucleosome remodeling and deacetylase complex regulates phosphatase and tensin homolog gene expression and function. J. Biol.Chem. 287, 27843-27850.
15. Salot, S., and Gude, R. (2013). MTA1-mediated transcriptional repression of SMAD7 in breast cancer cell lines. Eur. J.Cancer 49, 492-499.
16. Serin, M., Erkal, H.S., and Cakmak, A. (1999). Radiation therapy and concurrent cisplatin in management of locoregionally advanced nasopharyngeal carcinomas. Acta Oncol. 38, 1031-1035.
17. Shafee, N., Smith, C.R., Wei, S., Kim, Y., Mills, G.B., Hortobagyi, G.N., Stanbridge, E.J., and Lee, E.Y. (2008). Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res. 68, 3243-3250.
18. Singh, S.K., Clarke, I.D., Terasaki, M., Bonn, V.E., Hawkins, C., Squire, J., and Dirks, P.B. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821-5828.
19. Song, Q., Zhang, H., Wang, M., Song, W., Ying, M., Fang, Y., Li, Y., Chao, Y., and Zhu, X. (2013). MTA1 promotes nasopharyngeal carcinoma growth in vitro and in vivo. J.Exp.Clin.Cancer Res. 32, 54.
20. Spano, J.P., Busson, P., Atlan, D., Bourhis, J., Pignon, J.P., Esteban, C., and Armand, J.P. (2003). Nasopharyngeal carcinomas: an update. Eur. J.Pharmacol. 39, 2121-2135.
21. Venkatesha, V.A., Parsels, L.A., Parsels, J.D., Zhao, L., Zabludoff, S.D., Simeone, D.M., Maybaum, J., Lawrence, T.S., and Morgan, M.A. (2012). Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition. Neoplasia 14, 519-525.
22. Vinogradov, S., and Wei, X. (2012). Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine 7, 597-615.
23. Wang, H., Zhang, G., Zhang, H., Zhang, F., Zhou, B., Ning, F., Wang, H.S., Cai, S.H., and Du, J. (2014). Acquisition of epithelialmesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/beta-catenin/Snail signaling pathway. Eur. J. Pharmacol. 723, 156-166.
24. Zhang, Y., Ng, H.H., Erdjument-Bromage, H., Tempst, P., Bird, A., and Reinberg, D. (1999). Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 13, 1924-1935.